Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Genetics · Osteopetrosis

Subtypes and Genetics: The Blueprint of the Disease

At a Glance

Osteopetrosis is caused by genetic mutations that determine the disease's severity and subtype, such as infantile (MIOP) or adult-onset (ADO). Identifying the specific gene, like TCIRG1 or OSTM1, is crucial because it dictates whether a bone marrow transplant will effectively treat the condition.

Every case of osteopetrosis is unique because the condition is caused by several different variations in your genetic code. Identifying which gene is responsible is more than just a label—it is the roadmap your doctors use to determine if a bone marrow transplant will work or if other supportive care is needed [1][2].

Major Subtypes and How They Are Inherited

Osteopetrosis is classified by its severity and how it is passed down through families.

1. Malignant Infantile Osteopetrosis (MIOP/ARO)

This is a severe, early-onset form that is autosomal recessive. This means a child must inherit one copy of the mutated gene from each parent [3][4].

  • Symptoms: Usually appears in the first few months of life with vision loss, severe anemia, and a narrowed bone marrow space [5][6].
  • Outlook: Without a Hematopoietic Stem Cell Transplant (HSCT), this form is often fatal in early childhood [7][8].

2. Autosomal Dominant Osteopetrosis (ADO)

Also known as Albers-Schönberg disease, this form is autosomal dominant, meaning only one parent needs to pass on the gene for the condition to appear [9].

  • Symptoms: Symptoms often don’t appear until late childhood or adulthood. It is characterized by frequent fractures, bone pain, and sometimes infections of the jaw (osteomyelitis) [10][11].
  • Outlook: Most patients have a normal life expectancy but require careful orthopedic management to handle “brittle” bone fractures and severe dental oversight [10]. Transplants are not indicated for this form.

3. Carbonic Anhydrase II (CA II) Deficiency

This is a unique autosomal recessive subtype that affects more than just the bones. It involves a triad of symptoms: dense bones, renal tubular acidosis (a kidney issue where the blood becomes too acidic), and cerebral calcifications (calcium deposits in the brain) [12][13].

  • The Role of CA II: In healthy bodies, the Carbonic Anhydrase II enzyme helps osteoclasts produce the acid needed to dissolve bone [14]. It also helps the kidneys manage acid in the blood. Without it, both systems fail [15].

Why Genetics Dictate Treatment

Genetic testing is critical because some mutations affect the brain in ways that a transplant cannot fix.

Gene Mutation Common Subtype Transplant (HSCT) Effectiveness
TCIRG1 Infantile (ARO) Highly Effective: Often cures the bone and blood issues [16][17].
CLCN7 ADO or ARO Varies: Can be effective for bone issues, but some recessive forms cause severe brain damage that HSCT cannot stop [18][19].
OSTM1 Infantile (ARO) Limited: While it can help bone density, this mutation causes severe, progressive neurodegeneration that persists even after a transplant [19][20].

The OSTM1 and CLCN7 Warning

Finding a mutation in the OSTM1 or certain CLCN7 genes is a pivotal moment for a care team. These genes are active in the central nervous system, not just the bones [18]. In these specific cases, even if a transplant successfully “replaces” the bone-clearing cells, the underlying damage to the brain cells continues [19]. This is why molecular diagnosis (genetic testing) must happen as soon as possible—it helps families and doctors make the most informed decisions about whether the risks of a transplant are balanced by the likely benefits [1][21].

Common questions in this guide

What are the main subtypes of osteopetrosis?
The main subtypes include Malignant Infantile Osteopetrosis (a severe, early-onset form), Autosomal Dominant Osteopetrosis (a milder form appearing later in life), and Carbonic Anhydrase II Deficiency. Each subtype is caused by different genetic mutations and requires distinct treatments.
Why is genetic testing important for osteopetrosis?
Genetic testing identifies the exact gene mutation causing the disease, such as TCIRG1 or CLCN7. This helps doctors predict the severity of the condition and determine if a stem cell or bone marrow transplant will be an effective treatment.
Will a bone marrow transplant cure osteopetrosis?
A transplant can be highly effective for certain genetic forms like TCIRG1 mutations. However, for mutations like OSTM1, a transplant cannot stop the severe neurological damage that occurs, making careful genetic evaluation critical before proceeding.
What is Autosomal Dominant Osteopetrosis (ADO)?
Also known as Albers-Schönberg disease, ADO is a form of osteopetrosis where symptoms usually appear in late childhood or adulthood. Patients typically have a normal life expectancy but require ongoing care for frequent bone fractures and dental issues.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which gene mutation was found in my (or my child's) genetic test, and is it a 'loss-of-function' or 'gain-of-function' mutation?
  2. 2.Is the specific mutation we have associated with primary neurodegeneration? If so, will a bone marrow transplant prevent those neurological symptoms?
  3. 3.Have we checked for signs of 'Renal Tubular Acidosis' or brain calcifications that could point toward Carbonic Anhydrase II deficiency?
  4. 4.Based on this genetic subtype, is a Hematopoietic Stem Cell Transplant (HSCT) the recommended treatment, and what are the chances of success for this specific mutation?
  5. 5.If the mutation is CLCN7, is it the dominant form (ADO) or the recessive form (ARO), and how does that change our long-term outlook?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Molecular Heterogeneity of Osteopetrosis in India: Report of 17 Novel Variants.

    Arunachalam AK, Aboobacker FN, Sampath E, et al.

    Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2024; (40(3)):494-503 doi:10.1007/s12288-023-01732-4.

    PMID: 39011244
  2. 2

    One Disease, Many Genes: Implications for the Treatment of Osteopetroses.

    Penna S, Capo V, Palagano E, et al.

    Frontiers in endocrinology 2019; (10()):85 doi:10.3389/fendo.2019.00085.

    PMID: 30837952
  3. 3

    Clinical presentation and analysis of genotype-phenotype correlations in patients with malignant infantile osteopetrosis.

    Even-Or E, Schiesel G, Simanovsky N, et al.

    Bone 2022; (154()):116229 doi:10.1016/j.bone.2021.116229.

    PMID: 34624559
  4. 4

    Managing challenging pain and irritability in OSTM1 mutation-related infantile malignant osteopetrosis.

    Alotaibi Q, Dighe M

    BMJ case reports 2021; (14(5)) doi:10.1136/bcr-2021-242498.

    PMID: 34011644
  5. 5

    Malignant Infantile Osteopetrosis with Bone Marrow Involvement.

    Khadga M, M Raihanur Rahman AZ, Benzamin MD, et al.

    Kathmandu University medical journal (KUMJ) 2022; (20(77)):107-110.

    PMID: 36273302
  6. 6

    Malignant Infantile Osteopetrosis With Neurological and Hematological Complications: A Case Review.

    Abdulsalam TA, Elmiaari M, ALRomithi LD, et al.

    Cureus 2025; (17(6)):e85521 doi:10.7759/cureus.85521.

    PMID: 40625472
  7. 7

    A Rare Case of Malignant Infantile Osteopetrosis Presenting as Frontal Lobe Hemorrhage.

    Ali A, Bin Arif T, Khan S, et al.

    Cureus 2020; (12(7)):e9234 doi:10.7759/cureus.9234.

    PMID: 32821582
  8. 8

    Hematopoietic stem cell transplantation in a patient with osteopetrosis and mutation in CLCN7: long-term follow-up.

    Gaytán-Morales JF, Castorena-Villa I, Mendoza-Camargo FO, et al.

    Boletin medico del Hospital Infantil de Mexico 2021; (78(3)):225-233 doi:10.24875/BMHIM.20000105.

    PMID: 33651788
  9. 9

    Overlapping Phenotypes in Osteopetrosis and Pycnodysostosis in Asian-Indians.

    Kaur P, Panigrahi I, Kaur H, et al.

    Case reports in genetics 2021; (2021()):7133508 doi:10.1155/2021/7133508.

    PMID: 34777883
  10. 10

    Osteopetrosis in the pediatric patient: what the radiologist needs to know.

    McLuckey MN, Imel EA, Forbes-Amrhein MM

    Pediatric radiology 2024; (54(7)):1105-1115 doi:10.1007/s00247-024-05899-4.

    PMID: 38483591
  11. 11

    Osteopetrosis and related osteoclast disorders in adults: A review and knowledge gaps On behalf of the European calcified tissue society and ERN BOND.

    Funck-Brentano T, Zillikens MC, Clunie G, et al.

    European journal of medical genetics 2024; (69()):104936 doi:10.1016/j.ejmg.2024.104936.

    PMID: 38593953
  12. 12

    Carbonic Anhydrase II Deficiency: Unusual Presentation of the Arabic Mutation. A Case Report.

    Alayed Y, Alghamdi W, Alyousef R

    Global pediatric health 2024; (11()):2333794X241230873 doi:10.1177/2333794X241230873.

    PMID: 38328522
  13. 13

    Report of Another Mutation Proven Case of Carbonic Anhydrase II Deficiency.

    Satapathy AK, Pandey S, Chaudhary MR, et al.

    Journal of pediatric genetics 2019; (8(2)):91-94 doi:10.1055/s-0038-1675781.

    PMID: 31061753
  14. 14

    Continuous Compressive Force Induces Differentiation of Osteoclasts with High Levels of Inorganic Dissolution.

    Matsuike R, Nakai K, Tanaka H, et al.

    Medical science monitor : international medical journal of experimental and clinical research 2019; (25()):3902-3909 doi:10.12659/MSM.913674.

    PMID: 31129676
  15. 15

    Carbonic anhydrase II deficiency: report of a novel mutation.

    Alsharidi A, Al-Hamed M, Alsuwaida A

    CEN case reports 2016; (5(1)):108-112 doi:10.1007/s13730-015-0205-y.

    PMID: 28509178
  16. 16

    Clinical and molecular characterization of five Chinese patients with autosomal recessive osteopetrosis.

    Liang H, Li N, Yao RE, et al.

    Molecular genetics & genomic medicine 2021; (9(11)):e1815 doi:10.1002/mgg3.1815.

    PMID: 34545712
  17. 17

    Stem cell transplantation for osteopetrosis in patients beyond the age of 5 years.

    Stepensky P, Grisariu S, Avni B, et al.

    Blood advances 2019; (3(6)):862-868 doi:10.1182/bloodadvances.2018025890.

    PMID: 30885997
  18. 18

    Pathobiologic Mechanisms of Neurodegeneration in Osteopetrosis Derived From Structural and Functional Analysis of 14 ClC-7 Mutants.

    Di Zanni E, Palagano E, Lagostena L, et al.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2021; (36(3)):531-545 doi:10.1002/jbmr.4200.

    PMID: 33125761
  19. 19

    Malignant Infantile Osteopetrosis: A Case Report.

    Bubshait DK, Himdy ZE, Fadaaq O, Alshmas HI

    Cureus 2020; (12(1)):e6725 doi:10.7759/cureus.6725.

    PMID: 32015934
  20. 20

    Hematopoietic cell transplantation for a child with OSTM1 osteopetrosis.

    Overholt KM, Rose MJ, Joshi S, et al.

    Blood advances 2017; (1(4)):279-281 doi:10.1182/bloodadvances.2016002345.

    PMID: 29296943
  21. 21

    [Analysis of clinical presentation and genetic characteristics of malignant infantile osteopetrosis].

    Wei A, Zhu GH, Qin MQ, et al.

    Zhonghua er ke za zhi = Chinese journal of pediatrics 2023; (61(11)):1038-1042 doi:10.3760/cma.j.cn112140-20230822-00124.

    PMID: 37899344

This page explains osteopetrosis genetics and subtypes for educational purposes. Always consult a genetic counselor and your medical team to interpret specific gene mutations and treatment options.

Get notified when new evidence is published on Osteopetrosis and related disorders.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.